Anal Cancer: Progress on Combined-Modality and Organ Preservation

Current Problems in Cancer

Volumn 33, Issue 5, 2009, Pages 302-326

  Chan, Emily ^a   Kachnic, Lisa A ^b   Thomas Jr , Charles R ^c  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Division of Hematology and Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CISPLATIN; DOXORUBICIN; FLUOROURACIL; MITOMYCIN; MITOMYCIN C;

ANUS CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER RADIOTHERAPY; CANCER SURVIVAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MORBIDITY; ORGAN PRESERVATION; PROPORTIONAL HAZARDS MODEL; QUALITY OF LIFE; RADIATION DOSE; RISK FACTOR; SQUAMOUS CELL CARCINOMA; TUMOR VOLUME;

ANAL CANAL; ANUS NEOPLASMS; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HIV INFECTIONS; HUMANS; PROCTOSCOPY; PROGNOSIS; RISK FACTORS;

EID: 71649107448     PISSN: 01470272     EISSN: 15356345     Source Type: Journal    
DOI: 10.1016/j.currproblcancer.2009.10.003     Document Type: Article

References (49)

1. American Cancer Society. Cancer Facts and Figures 2009, vol 4 (2009), American Cancer Society, Atlanta, GA
2. Ryan D.P., Comptom C.C., and Mayer R.J. Carcinoma of the anal canal. N Engl J Med 342 (2000) 792-800
3. Daling J.R., Weiss N.S., Hislop T.G., Maden C., Coates R.J., Sherman K.J., et al. Sexual practices, sexually transmitted diseases, and the incidence of anal cancer. N Engl J Med 317 (1987) 973-977
4. Holly E.A., Whittemore A.S., Aston D.A., Ahn D.K., Nickoloff B.J., and Kristiansen J.J. Anal cancer incidence: genital warts, anal fissure or fistula, hemorrhoids, and smoking. J Natl Cancer Inst 81 (1989) 1726-1731
5. Frisch M., Glimelius B., van den Brule A.J., Wohlfahrt J., Meijer C.J., Walboomers J.M., et al. Sexually transmitted infection as a cause of anal cancer. N Engl J Med 337 (1997) 1350-1358
6. Penn I. Cancers of the anogenital region in renal transplant recipients. Analysis of 65 cases. Cancer 58 (1986) 611-616
7. Arends M.J., Benton E.C., McLaren K.M., Stark L.A., Hunter J.A., and Bird C.C. Renal allograft recipients with high susceptibility to cutaneous malignancy have an increased prevalence of human papillomavirus DNA in skin tumours and a greater risk of anogenital malignancy. Br J Cancer 75 (1997) 722-728
8. Palefsky J.M., Holly E.A., Gonzales J., Berline J., Ahn D.K., and Greenspan J.S. Detection of human papillomavirus DNA in anal intraepithelial neoplasia and anal cancer. Cancer Res 51 (1991) 1014-1019
9. Bedimo R.J., McGinnis K.A., Dunlap M., Rodriguez-Barradas M.C., and Justice A.C. Incidence of non-AIDS-defining malignancies in HIV-infected versus non-infected patients in the HAART era: impact of immunosuppression. J Acquir Immune Defic Syndr 52 (2009) 203-208
10. Oehler-Jänne C., Huguet F., Provencher S., Seifert B., Negretti L., Riener M.O., et al. HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: a multicentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy. J Clin Oncol 26 (2008) 2550-2557
11. Gunderson L.L., Moughan J., Ajani J.A., et al. Anal carcinoma: Impact of TN category of disease on survival and disease relapse in the US GI InterGroup RTOG 98-11 phase III trial. Proceedings of the GI Cancer Symposium, Orlando, FL (2010)
12. Bilimoria K.Y., Bentrem D.J., Rock C.E., Stewart A.K., Ko C.Y., and Halverson A. Outcomes and prognostic factors for squamous cell carcinoma of the anal canal: analysis of patients from the National Cancer Database. Dis Colon Rectum 52 (2009) 624-631
13. Ajani J.A., Winter K.A., Gunderson L.L., et al. Intergroup RTOG 98-11: a phase III randomized study of 5-fluorouracil (5-FU), mitomycin, and radiotherapy versus 5-fluorouracil, cisplatin and radiotherapy in carcinoma of the anal canal. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 24 18S (2006) 4009
14. Myerson R.J., Outlaw E.D., Chang A., Birnbaum E.H., Fleshman J.W., Grigsby P.W., et al. Radiotherapy for epidermoid carcinoma of the anus: thirty years' experience. Int J Radiat Oncol Biol Phys 75 (2009) 428-435
15. Beck D.E., and Karulf R.E. Combination therapy for epidermoid carcinoma of the anal canal. Dis Colon Rectum 37 (1993) 1118-1125
16. Salmon R.J., Fenton J., Asselain B., Mathieu G., Girodet J., Durand J.C., et al. Treatment of epidermoid anal canal cancer. Am J Surg 147 (1984) 43-48
17. Papillon J., Mayer M., Montbarbon J.F., Gerard J.P., Chassard J.L., and Bailly C. A new approach to the management of epidermoid carcinoma of the anal canal. Cancer 51 (1983) 1830-1837
18. Nigro N.D., Vaitkevicius V.K., and Considine B. Combined therapy for cancer of the anal cancer: a preliminary report. Dis Colon Rectum 17 (1974) 354-356
19. Buroker T.R., Nigro N., Bradley G., Pelok L., Chomchai C., Considine B., et al. Combined therapy for cancer of the anal canal: a follow up report. Dis Colon Rectum 20 (1977) 677-678
20. Nigro N.D., Vaitkevicius V.K., Buroker T., Bradley G.T., and Considine B. Combined therapy for cancer of the anal canal. Dis Colon Rectum 24 (1981) 73-75
21. Nigro N.D., Seydel H.G., Considine B., Vaitkevicius V.K., Leichman L., and Kinzie J.J. Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canal. Cancer 51 (1983) 1826-1829
22. UKCCCR Anal Cancer Trial Working Party. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. Lancet 348 (1996) 1049-1054
23. Bartelink H., Roelofsen F., Eschwege F., Rougier P., Bosset J.F., Gonzalez D.G., et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 15 (1997) 2040-2049
24. Flam M., John M., Pajak T.F., Patrelli N., Myerson R., Doggett S., et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 14 (1996) 2527-2539
25. Hung A., Crane C., Delclos M., Ballo M., Ajani J., Lin E., et al. Cisplatin-based combined modality therapy for anal carcinoma. Cancer 97 (2003) 1195-1202
26. Ajani H.A., Winter K.A., Gunderson L.L., et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. J Am Med Assoc 299 (2008) 1914-1921
27. Ajani J.A., Winter K.A., Gunderson L.L., Pedersen J., Benson III A.B., Thomas Jr. C.R., et al. US Intergroup Anal Carcinoma Trial: tumor diameter predicts for colostomy. J Clin Oncol 27 (2009) 1116-1121
28. James R., Wan S., Glynne-Jones R., et al. A randomized trial of chemoradiation using mitomycin or cisplatin, with or without maintenance cisplatin/5-FU in squamous cell carcinoma of the anus (ACT II). 2009 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 27 18S (2009) LBA4009
29. Salama J.K., Mell L.K., Schomas D.A., Miller R.C., Devisetty K., Jani A.B., et al. Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. J Clin Oncol 25 (2007) 4581-4586
30. Kachnic L., Winter R., Myerson R., et al. RTOC 0529: a phase II evaluation of dose-painted IMRT in combination with 5-fluorouracil and mitomycin-C for reduction of acute morbidity in carcinoma of the anal canal. Proceedings of the 51st Annual ASTRO Meeting, Chicago, IL. J Radiat Oncol Biol 75 (2009) S1-S5
31. Doniec J.M., Schniewind B., Kovács G., Kahlke V., Loehnert M., and Kremer B. Multimodal therapy of anal cancer added by new endosonographic-guided brachytherapy. Surg Endosc 20 (2006) 673-678
32. 192Ir implantation: a 10 year experience. Brachytherapy 3 (2004) 95-100
33. Oehler-Jänne C., Seifert B., Lütolf U.M., Studer G., Glanzmann C., and Ciernik I.F. Clinical outcome after treatment with a brachytherapy boost versus external beam boost for anal carcinoma. Brachytherapy 6 (2007) 218-226
34. Bower M., Powles T., Newsom-Davis T., Thirlwell C., Stebbing J., Mandalia S., et al. HIV-associated anal cancer: has highly active antiretroviral therapy reduced the incidence or improved the outcome?. J Acquir Immune Defic Syndr 37 (2004) 1563-1565
35. Cru-Cianflone N., Hullsiek K.H., Weintrob A., et al. Anal cancers among HIV-infected persons: HAART is not slowing rising incidence (2009), Fifth International AIDS Society. Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa
36. Kim J.H., Sarani B., Orkin B.A., Young H.A., White J., Tannebaum I., et al. HIV-positive patients with anal carcinoma have poorer treatment tolerance and outcome than HIV-negative patients. Dis Colon Rectum 44 (2001) 1496-1502
37. Holland J.M., and Swift P.S. Tolerance of patients with human immunodeficiency virus and anal carcinoma to treatment with combined chemotherapy and radiation therapy. Radiology 193 (1994) 251-254
38. Peddada A.V., Smith D.E., Rao A.R., Frost D.B., and Kagan A.R. Chemotherapy and low-dose radiotherapy in the treatment of HIV-infected patients with carcinoma of the anal canal. Int J Radiat Oncol Biol Phys 37 (1997) 1101-1105
39. Hoffman R., Welton M.L., Klencke B., Weinberg V., and Krieg R. The significance of pretreatment CD4 count on the outcome and treatment tolerance of HIV-positive patients with anal cancer. Int J Radiat Oncol Biol Phys 44 (1999) 127-131
40. Edelman S., and Johnstone P.A.S. Combined modality therapy for HIV-infected patients with squamous cell carcinoma of the anus: outcomes and toxicities. Int J Radiat Oncol Biol Phys 66 (2006) 206-211
41. Wexler A., Berson A.M., Goldstone S.E., Waltzman R., Penzer J., Maisonet O.G., et al. Invasive anal squamous-cell carcinoma in the HIV-positive patient: outcome in the era of highly active antiretroviral therapy. Dis Colon Rectum 51 (2008) 73-81
42. Hogg M.E., Popowich D.A., Wang E.C., Kiel K.D., Stryker S.J., and Halverson A.L. HIV and anal cancer outcomes: a single institution's experience. Dis Colon Rectum 52 (2009) 891-897
43. Chiao E.Y., Giordano T.P., Richardson P., and El-Serag H.B. Human immunodeficiency virus-associated squamous cell cancer of the anus: epidemiology and outcomes in the highly active antiretroviral therapy era. J Clin Oncol 26 (2008) 474-479
44. Renhan A.G., Saunders M.P., Schofield P.F., and O'Dwyer S.T. Patterns of local disease failure and outcome after salvage surgery in patients with anal cancer. Br J Surg 92 (2005) 605-614
45. Akbari R.P., Paty P.B., Guillem J.G., Weiser M.R., Temple L.K., Minsky B.D., et al. Oncologic outcomes of salvage surgery for epidermoid carcinoma of the anus initially managed with combined modality therapy. Dis Colon Rectum 47 (2004) 1136-1144
46. Schiller D.E., Cummings B.J., Rai S., Le L.W., Last L., Davey P., et al. Outcomes of salvage surgery for squamous cell carcinoma of the anal canal. Ann Surg Oncol 14 (2007) 2780-2789
47. Jhawer M., Mani S., Lefkopoulou M., Hahn R.G., Harris J., Catalano P.J., et al. Phase II study of mitomycin-C, Adriamycin, cisplatin (MAP) and bleomycin-CCNU in patients with advanced cancer of the anal canal: an Eastern Cooperative Oncology Group study E7272. Investig New Drugs 24 (2006) 447-454
48. Phan L.K., and Hoff P.M. Evidence of clinical activity for cetuximab combined with irinotecan in a patient with refractory anal canal squamous-cell carcinoma: report of a case. Dis Colon Rectum 50 (2007) 395-398
49. Schellens J.H.M. Capecitabine. Oncologist 12 (2007) 152-155